Straits Times Index
3,348.87 +12.28 (+0.37%) S&P 500
5,275.04 -2.47 (-0.05%) Dow
38,504.89 -181.43 (-0.47%) Nasdaq
16,803.71 +68.69 (+0.41%) Bitcoin USD
69,193.53 +1,039.97 (+1.53%) CMC Crypto 200
1,499.47 +31.53 (+2.15%)
CSL Limited (CMXHF)
| Previous close | 184.70 |
| Open | 185.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 180.05 - 189.00 |
| 52-week range | 144.81 - 207.67 |
| Volume | |
| Avg. volume | 634 |
| Market cap | 91.335B |
| Beta (5Y monthly) | 0.30 |
| PE ratio (TTM) | 37.20 |
| EPS (TTM) | 5.08 |
| Earnings date | 13 Aug 2024 |
| Forward dividend & yield | 2.46 (1.30%) |
| Ex-dividend date | 11 Mar 2024 |
| 1y target est | N/A |
PR NewswireCSL Seqirus, a Proud Champion of Pandemic Preparedness, Announces U.S. Government Award in Response to Avian Influenza
CSL Seqirus, a business of CSL (ASX: CSL), was selected by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to complete the fill and finish process of pre-pandemic vaccine for the U.S. government as part of the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS) program. This acquisition of pre-pandemic vaccine will increase BARDA's sto
PR NewswireNature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine
Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) today announce Nature Communications has published results from an integrated phase 1/2/3a/3b study evaluating the safety, immunogenicity, and efficacy of ARCT, 154, a novel self-amplifying (sa-mRNA) COVID-19 vaccine and the world's first approved sa-mRNA COVID-19 vaccine.
PR NewswireRecently Published Real-World Evidence Study Shows Effectiveness of Cell-Based Quadrivalent Influenza Vaccine Over Three Seasons
CSL Seqirus, a business of CSL (ASX: CSL), today announced a real-world evidence (RWE) study recently published in Open Forum Infectious Diseases (OFID), showing that a cell-based quadrivalent influenza vaccine (QIVc) prevented more test-confirmed influenza cases among individuals 4–64 years of age compared with the egg-based quadrivalent influenza vaccine (QIVe) over three consecutive U.S. influenza seasons (2017–2020).1 These data add to the growing wealth of evidence supporting the benefits o
